Home
Squadron Capital Management reported a 7% stake in Relmada Therapeutics RLMD · 7,350,000 sh · amendment · passive holder
Trade details
- Type
- 5% stake report
- Report
- 13G passive · amendment
- Stake
- 7%
- Last report
- 9.9% · filed 26/02/17
- Shares held
- 7,350,000 sh
- Class
- Common stock, $0.001 par value per share
- Event date
- 26/06/30
- Filed
- 26/08/14
7% stake · −2.9pp from the last report
- Stake
- 7%
- Last report
- 9.9%
- Since last report
- −2.9pp
Relmada Therapeutics trades, last 26 weeks
What else happened in Relmada Therapeutics around then
Filed or reported within 30 days of the trade day · 05/31~07/30Squadron Capital Management's other 5% stake reports
- Squadron Capital Management
5% stakeTraws Pharma
5% stakeTraws Pharma
TRAW
0% stake
0 sh
0% stake
Filed 08/14
- Squadron Capital Management
5% stakeNextCure
5% stakeNextCure
NXTC
1.6% stake
64,464 sh
1.6% stake
Filed 08/14
- Squadron Capital Management
5% stakeLipocine
5% stakeLipocine
LPCN
9.8% stake
810,000 sh
9.8% stake
Filed 08/14
- Squadron Capital Management
5% stakeC4 Therapeutics
5% stakeC4 Therapeutics
CCCC
6.9% stake
7,600,000 sh
6.9% stake
Filed 08/14
- Squadron Capital Management
5% stakeQuince Therapeutics
5% stakeQuince Therapeutics
QNCX
5.6% stake
55,173 sh
5.6% stake
Filed 08/04
